Aspen Neuroscience, Inc.

Aspen Neuroscience, Inc. publicly filed a registration statement on Form S-1 on Oct 9, 2026 for a proposed initial public offering on Nasdaq Global Select, and has not yet priced. Underwriters named in the filing: Leerink Partners, UBS, Piper Sandler and Stifel and others.

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine company developing autologous iPSC-derived cell therapies for neurodegenerative diseases. Its lead product candidate, sasineprocel, is a single-dose autologous cell therapy being evaluated in a Phase 1/2a trial for Parkinson's disease.

Status

Filed, not priced

Exchange

Nasdaq Global Select

First filed

Oct 9, 2026

Latest amendment

Oct 9, 2026

Underwriters

Leerink Partners, UBS, Piper Sandler, Stifel and Oppenheimer

Sector

Biotech & pharma

Country / state

CA